Is high HDL cholesterol always good?

Annals of Medicine

Volumn 41, Issue 1, 2009, Pages 11-18

  Olsson, Anders G ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b NONE   (Sweden)

Author keywords

Anacetrapib; Atherosclerosis; CETP inhibition; CHD prevention; Cholesterol ester transfer protein (CETP); Coronary heart disease (CHD); Dalcetrapib; High density lipoprotein (HDL); Torcetrapib

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANACETRAPIB; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PLACEBO; TORCETRAPIB; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTERY INTIMA PROLIFERATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG INHIBITION; DRUG MEGADOSE; DYSLIPIDEMIA; GENE MUTATION; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; HUMANS; QUINOLINES; RISK; TREATMENT OUTCOME;

EID: 60549107038     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890802609534     Document Type: Review

References (40)

1. Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma: II. In atherosclerosis and related conditions. Am J Med. 1951;11:480-93.
2. Nikkilä E. Studies on the lipid-protein relationship in normal and pathological sera and the effect of heparin on serum lipoproteins. Scand J Clin Lab Invest. 1953;5(Suppl 8):9-100.
3. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;305:16-19.
4. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977;1:965-8.
5. Gordon T, Castelli W, Hjortland M, Kannel W, Dawber T. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-14.
6. Tall A. An overview of reverse cholesterol transport. Eur Heart J. 1998;19 Suppl A:A31-5.
7. Schmitz G, Kaminski W, Porsch-Ozcürümez M, Klucken J, Orsó E, Bodzioch M, et al. ATP-binding cassette transporter A1 (ABCA1) in macrophages: a dual function in inflammation and lipid metabolism? Pathobiology. 1999;67:236-40.
8. Klucken J, Buchler C, Orso E, Kaminski WE, Porsch-Ozcurumez M, Liebisch G, et al. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci U S A. 2000;97:817-22.
9. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7:365-75.
10. Barter PJ, Nicholls S, Rye K-A, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95:764-72.
11. Vaisar T, Pennathur S, Green P, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746-56.
12. Canner P, Berge K, Wenger N, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-55.
13. Carlson L, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Medica Scandinavica. 1988;223:405-18.
14. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94:706-14.
15. Wild S, Byrne CD. Time to rethink high-density lipoprotein? Heart. 2008;94:692-4.
16. Inazu A, Brown M, Hesler C, Agellon LB, Koizumi J, Takata K, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234-8.
17. Hirano K-I, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan: marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 1997;17:1053-9.
18. Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res. 2004;45:948-53.
19. Watts G. The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis. Clin Sci (Lond). 2002;103:595-7.
20. Boekholdt SM, Kuivenhoven J-A, Wareham NJ, Peters RJG, Jukema JW, Luben R, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population Study. Circulation. 2004;110:1418-23.
21. Borggreve SE, Hillege HL, Dallinga-Thie GM, de Jong PE, Wolffenbuttel BHR, Grobbee DE, et al. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J. 2007;28:1012-8.
22. Fielding CJ, Havel RJ. Cholesteryl ester transfer protein: friend or foe? J Clin Invest. 1996;97:2687-88.
23. Hennessy L, Kunitake S, Kane J. Apolipoprotein A-I-containing lipoproteins, with or without apolipoprotein A-II, as progenitors of pre-beta high-density lipoprotein particles. Biochemistry. 1993;32:5759-65.
24. Hirano K, Yamashita S, Matsuzawa Y. Pros and cons of inhibiting CETP. Curr Opin Lipidol. 2000;11:589-96.
25. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-22.
26. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ESG, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: The IDEAL and EPIC-Norfolk Studies. J Am Coll Cardiol. 2008;51:634-42.
27. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52.
28. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224-33.
29. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-300.
30. Sirtori C, Mombelli G. Viability of developing CETP inhibitors. Cardiovasc Ther. 2008;26:135-46.
31. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Rezzonico L, Chiesa G, et al. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis. 1989;9:462-9.
32. Baldassarre D, Franceschini G, Peruzzotti G, Brusoni B, Sirtori CR. Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. J Cardiovasc Pharmacol. 1997;30:784-9.
33. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka atherosclerosis trial (FAST). J Am Coll Cardiol. 2002;39:610-6.
34. Walldius G, Erikson U, Olsson AG, Bergstrand L, Hådell K, Johansson J, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol. 1994;74:875-83.
35. Johansson J, Olsson AG, Bergstrand L, Schafer Elinder L, Nilsson S, Erikson U, et al. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia: a Probucol Quantitative Regression Swedish Trial (PQRST) Report. Arterioscler Thromb Vasc Biol. 1995;15:1049-56.
36. Ansell B, Fonarow G, Fogelman A. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 2007;18:427-34.
37. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels: evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51:2199-211.
38. van Acker BAC, Botma G-J, Zwinderman AH, Kuivenhoven JA, Dallinga-Thie GM, Sijbrands EJG, et al. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. Atherosclerosis. 2008;200:161-7.
39. de Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, de Graaf J, Zwinderman AH, Posma JL, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase ii dose-response study. Circulation. 2002;105:2159-65.
40. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370:1907-14.